Human B7-H4 PE-conjugated Antibody
Human B7-H4 PE-conjugated Antibody Summary
Phe29-Ser258
Accession # Q7Z7D3
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of B7‑H4 in HEK293 Human Cell Line Transfected with Human B7-H4 and eGFP by Flow Cytometry. HEK293 human embryonic kidney cell line transfected with human B7-H4 and eGFP were stained with either (A) Mouse Anti-Human B7-H4 PE-conjugated Monoclonal Antibody (Catalog # FAB6576P) or (B) Mouse IgG2BPhycoerythrin Isotype Control (Catalog # IC0041P). View our protocol for Staining Membrane-associated Proteins.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: B7-H4
B7-H4, also known as VTCN1, B7x and B7S1, is a 50‑80 kDa glycosylated member of the BTN/MOG family of immunomodulatory protein (1, 2). Mature human B7-H4 consists of a 235 amino acid (aa) extracellular domain (ECD) with two Ig-like V-type domains, a 21 aa transmembrane segment, and a 2 aa cytoplasmic tail (3-5). Within the ECD, human B7-H4 shares 90% aa sequence identity with mouse and rat B7-H4. It shares 22%-28% aa sequence identity with human B7-1, B7-2, B7-H1, B7-H2, B7-H3, and PD‑L2. Alternate splicing of human B7-H4 generates an additional isoform that lacks the first Ig-like domain. B7-H4 is expressed on the surface of activated lymphocytes, macrophages, monocytes, dendritic cells, epithelial cells, and bone marrow-derived mesenchymal stem cells
(4-8). Following binding to activated T cells, B7-H4 serves as a co‑inhibitor of the T cell response. This is accomplished by reverse signaling that can induce either cell cycle arrest, or apoptosis in B7-H4 expressing cells (2-5, 9, 10). B7‑H4 is up‑regulated in several carcinomas in correlation with tumor progression and metastasis (2, 7, 11, 12). A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, and is correlated with advanced disease status (13-15). Soluble B7‑H4 functions as a decoy molecule that blocks the inhibitory influence of B7‑H4 on immune activation (15). Despite evidence for the involvement of B7-H4 in immune regulation, mice deficient in its expression do not show significant immune deficiencies, suggesting compensation by other molecules in vivo (16).
- Yi, K.H. and L. Chen (2009) Immunol. Rev. 229:145.
- Guo, Y. and A.Y. Wang (2015) Front. Immunol. 6:421.
- Zang, X. et al. (2003) Proc. Natl. Acad. Sci. USA 100:10388.
- Prasad, V.R. et al. (2003) Immunity 18:863.
- Sica, G.L. et al. (2003) Immunity 18:849.
- Kryczek, I. et al. (2006) J. Exp. Med. 203:871.
- Tringler, B. et al. (2005) Clin. Cancer Res. 11:1842.
- Xue, Q. et al. (2010) Stem Cells Dev. 19:27.
- Song, H. et al. (2008) Cancer Lett. 266:227.
- Park, G.B. et al. (2009) Immunology 128:360.
- Zang, X. et al. (2007) Proc. Natl. Acad. Sci. USA 104:19458.
- Krambeck, A.E. et al. (2006) Proc. Natl. Acad. Sci. USA 103:10391.
- Simon, I. et al. (2006) Cancer Res. 66:1570.
- Thompson, R.H. et al. (2008) Cancer Res. 68:6054.
- Azuma, T. et al. (2009) PloS Med. 6:e1000166.
- Suh, W.-K. et al. (2006) Mol. Cell. Biol. 26:6403.
Product Datasheets
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human B7-H4 PE-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human B7-H4 PE-conjugated Antibody and earn rewards!
Have you used Human B7-H4 PE-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
